On May 3, 2016 Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) reported a conference call on Thursday, May 5, 2016 at 4:30 p.m. ET to further update the market on its Manocept macrophage targeting programs for immunodiagnostic and immunotherapeutic applications (Press release, Navidea Biopharmaceuticals, MAY 3, 2016, View Source/phoenix.zhtml?c=68527&p=RssLanding&cat=news&id=2164146" target="_blank" title="View Source/phoenix.zhtml?c=68527&p=RssLanding&cat=news&id=2164146" rel="nofollow">View Source [SID:1234511844]). Schedule your 30 min Free 1stOncology Demo! As mentioned on our previous call, we are eager to keep an open channel of discussion with investors regarding the important developments with the Manocept technology. We will devote a substantial portion of the call to Q&A as we want to make certain we address the subjects that are important to investors. We plan to continue discussing the progress of this promising technology during regularly scheduled Macrophage Therapeutics update calls.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference Call Details
Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, View Source, approximately two to four hours after the live event.
Event: Navidea and Macrophage Therapeutics Manocept Program Update Call
Date/Time: Thursday, May 5, 2016 at 4:30 p.m. ET
Webcast Link:
View Source
Dial-in Number – US: (855) 897-5884
Dial in Number – Int’l: (720) 634-2940
Participant Passcode: 5852350
Replay
A webcast replay will be available on the Investor Relations section of our website at View Source for 30 days.
About Manocept CD206 Immunotargeting Platform for Therapeutics Development
Manocept CD206 Immunotargeting Platform is a proprietary mannose-containing, receptor-directed technology platform designed to engineer novel, synthetic receptor targeted imaging agents and therapeutics for cancer and other diseases. Manocept’s unique structural and molecular properties enable the design of novel immuno-constructs that selectively target and bind to CD206 (mannose receptor) and other C-type Lectins found on activated, disease-associated macrophages and tumor associated macrophages (TAMs). The Manocept CD206 Immunotargeting Platform provides a novel and valuable approach to the design of drug molecules targeting CD206 disease-associated macrophages for therapeutic purposes.